Letybo (Botulinum Toxin Type A)

Botulinum toxin type A blocks the release of the neurotransmitter acetylcholine at the neuromuscular junction. It cleaves the SNAP‑25 protein, preventing synaptic vesicle fusion and thereby inhibiting muscle contraction. This reversible paralysis lasts for weeks to months, after which normal nerve function gradually returns.

The dose of Letybo is determined by the prescribing clinician based on the specific indication, treatment area, and individual patient factors. Dosing units are expressed in international units (U) and are tailored to achieve the desired therapeutic effect while minimizing adverse reactions.

Safety data for Letybo in pregnant or lactating women are limited, and the product is generally classified as contraindicated or to be used only when the potential benefit justifies the potential risk. Clinicians should evaluate the risk‑benefit profile before prescribing to this population.

To request Letybo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and the necessary import documentation.

Letybo contains botulinum toxin type A, the same neurotoxin class found in other marketed products such as Botox® and Dysport®. While the core mechanism is identical, differences may exist in formulation, unit potency, approved indications, and regulatory status. Clinicians choose a product based on clinical experience, dosing equivalence, and the specific therapeutic goals.

Letybo must be stored at 2‑8 °C in a refrigerator, protected from light, and should never be frozen or shaken. The product should be kept in its original packaging until use, and any reconstituted solution should be used within the time frame specified by the manufacturer to maintain potency.

Letybo is administered by a qualified healthcare professional as an intramuscular injection. The injection sites are selected based on the targeted muscle groups or sweat glands relevant to the indication. Proper aseptic technique and accurate dosing are essential to achieve the desired therapeutic effect and reduce the risk of adverse events.

Serious adverse events, although rare, can include dysphagia, ptosis, respiratory compromise, systemic spread of toxin leading to generalized muscle weakness, and severe allergic reactions such as anaphylaxis. Patients should be monitored closely after injection, especially when treating areas near the airway or eyes, and instructed to seek immediate medical attention if these symptoms occur.

Letybo is contraindicated in individuals with a known hypersensitivity to botulinum toxin type A, those with active infection at the planned injection site, and patients with neuromuscular transmission disorders such as myasthenia gravis or Lambert‑Eaton syndrome. Caution is also advised for pregnant or nursing women, and the product should only be used under the supervision of a qualified prescriber.